KAHR develops innovative immuno-recruitment cancer drugs
that activate immune responses by converting cancer camouflage
into beacons for the immune system to attack
that activate immune responses by converting cancer camouflage
into beacons for the immune system to attack
Synergistic recruitment and activation of innate
and adaptive anti-cancer immunity
with Multifunctional Immuno-Recruitment Proteins (MIRP)
SIRPα
- Binds CD47 on tumor cells
- Prevents “don’t eat me” signals
- Phagocytes ingest tumor cells
41BBL
- Binds 41BB receptor on T cells
- T-cell activation and proliferation
- T-cell induced tumor killing
Unique Features
Synergistic effect of
innate and adaptive
anticancer immunity
Trimeric structures for increased
specificity and optimal immune
cell activation
Conditional and
tumor-localized immune
cell recruitment
Differentiated PK/PD
relationships for wider
therapeutic window
Potential for solid
and hematological
malignancies
Contact Us
KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com